目的探讨桑枝总生物碱联合高压氧治疗对改善老年2型糖尿病患者稳态模型胰岛素抵抗指数(HOMA-IR)及稳态模型胰岛β细胞功能指数(HOMA-β)等指标的作用。方法选择老年糖尿病患者为治疗对象,根据患者主观参与意愿分为对照组、高压氧组、生...目的探讨桑枝总生物碱联合高压氧治疗对改善老年2型糖尿病患者稳态模型胰岛素抵抗指数(HOMA-IR)及稳态模型胰岛β细胞功能指数(HOMA-β)等指标的作用。方法选择老年糖尿病患者为治疗对象,根据患者主观参与意愿分为对照组、高压氧组、生物碱组和联合组。对照组行常规治疗。高压氧组在对照组基础上增加高压氧治疗。生物碱组在对照组基础上口服桑枝总生物碱片治疗。联合组在对照组基础上联合高压氧疗法和桑枝总生物碱片治疗。治疗后,从患者血糖、稳态模型胰岛素抵抗指数(HOMA-IR)、稳态模型胰岛β细胞功能指数(HOMA-β)、C-肽(C-P)、不良反应发生率、治疗效果等方面进行比较。结果联合组空腹血糖(FBG)显著低于对照组、高压氧组和生物碱组(P<0.05)。生物碱组和联合组餐后2 h血糖(2 h BG)显著低于对照组和高压氧组(P<0.05)。生物碱组HOMA-IR低于对照组和高压氧组,联合组HOMA-IR低于对照组、高压氧组和生物碱组,差异均有统计学意义(P<0.05)。生物碱组HOMA-β、C-P高于对照组和高压氧组,联合组HOMA-β、C-P高于对照组、高压氧组和生物碱组,差异均有统计学意义(P<0.05)。联合组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。4组不良反应发生率差异无统计学意义(P>0.05)。结论桑枝总生物碱联合高压氧治疗可有效改善老年2型糖尿病患者HOMA-IR及HOMA-β等指标,提高治疗效果。展开更多
目的探讨游离脂肪酸(FFA)、胰岛素抵抗指数与前清蛋白比值(HOMA-IR/PAB)、红细胞分布宽度(RDW)预测急性脑梗死(ACI)患者病情转归的价值。方法选取2019年4月—2021年1月西安市第三医院收治的118例ACI患者,根据30 d病情转归分为不良组(n=...目的探讨游离脂肪酸(FFA)、胰岛素抵抗指数与前清蛋白比值(HOMA-IR/PAB)、红细胞分布宽度(RDW)预测急性脑梗死(ACI)患者病情转归的价值。方法选取2019年4月—2021年1月西安市第三医院收治的118例ACI患者,根据30 d病情转归分为不良组(n=28)、良好组(n=90),比较两组基线资料、治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW水平,应用Spearman及偏相关性分析治疗前、治疗后7 d FFA、HOMAIR/PAB、RDW与mRS评分关系,采用受试者工作特征曲线(ROC)及ROC下面积(AUC)分析治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW预测病情转归的价值。结果不良组入院时NIHSS评分与良好组比较,差异有统计学意义(P<0.05);不良组治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW均高于良好组(P<0.05);治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW与mRS评分呈正相关(P<0.05);将入院时NIHSS评分控制后,治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW仍与mRS评分相关(P<0.05);治疗7 d后FFA、HOMA-IR/PAB、RDW及联合预测病情转归不良的AUC依次为0.868、0.867、0.881、0.920,均大于治疗前对应指标的AUC。结论ACI病情不良转归患者FFA、HOMA-IR/PAB、RDW升高,均与病情转归有关,联合检测有望成为预测患者病情转归的标志物,为临床提供准确、客观、量化的参考信息。展开更多
Polycystic ovarian syndrome (PCOS) is an endocrine disorder that affects women of reproductive age and is characterized by hyperandrogenism, unpredictable ovulation, and a polycystic ovary shape. It is accompanied by ...Polycystic ovarian syndrome (PCOS) is an endocrine disorder that affects women of reproductive age and is characterized by hyperandrogenism, unpredictable ovulation, and a polycystic ovary shape. It is accompanied by metabolic problems, such as obesity and insulin resistance (IR). Factors contributing to PCOS include genetics, epigenetic changes, environmental factors, oxidative stress, chronic inflammation, mitochondrial dysfunction, and metabolic abnormalities. Insulin resistance is the most prevalent classical phenotype, and metformin was the first insulin-sensitizing drug to be used to study its role. Metformin, derived from galegine, inhibits mitochondrial function, activates AMPK, enhances hepatic insulin sensitivity, and lowers the risk of type 2 diabetes in PCOS patients. It also affects tumor growth, with a 30% reduction in the overall tumor onsets in T2DM patients. Metformin treatment has been linked to low rates of multiple pregnancies, increased fetal concentrations of sex hormone-binding globulin, and decreased levels of inflammatory cytokines. It can reduce the risk of endometrial cancer, type 2 diabetes mellitus, cardiovascular disease, dyslipidemia, and hypertension in women with PCOS.展开更多
文摘目的探讨桑枝总生物碱联合高压氧治疗对改善老年2型糖尿病患者稳态模型胰岛素抵抗指数(HOMA-IR)及稳态模型胰岛β细胞功能指数(HOMA-β)等指标的作用。方法选择老年糖尿病患者为治疗对象,根据患者主观参与意愿分为对照组、高压氧组、生物碱组和联合组。对照组行常规治疗。高压氧组在对照组基础上增加高压氧治疗。生物碱组在对照组基础上口服桑枝总生物碱片治疗。联合组在对照组基础上联合高压氧疗法和桑枝总生物碱片治疗。治疗后,从患者血糖、稳态模型胰岛素抵抗指数(HOMA-IR)、稳态模型胰岛β细胞功能指数(HOMA-β)、C-肽(C-P)、不良反应发生率、治疗效果等方面进行比较。结果联合组空腹血糖(FBG)显著低于对照组、高压氧组和生物碱组(P<0.05)。生物碱组和联合组餐后2 h血糖(2 h BG)显著低于对照组和高压氧组(P<0.05)。生物碱组HOMA-IR低于对照组和高压氧组,联合组HOMA-IR低于对照组、高压氧组和生物碱组,差异均有统计学意义(P<0.05)。生物碱组HOMA-β、C-P高于对照组和高压氧组,联合组HOMA-β、C-P高于对照组、高压氧组和生物碱组,差异均有统计学意义(P<0.05)。联合组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。4组不良反应发生率差异无统计学意义(P>0.05)。结论桑枝总生物碱联合高压氧治疗可有效改善老年2型糖尿病患者HOMA-IR及HOMA-β等指标,提高治疗效果。
文摘目的探讨游离脂肪酸(FFA)、胰岛素抵抗指数与前清蛋白比值(HOMA-IR/PAB)、红细胞分布宽度(RDW)预测急性脑梗死(ACI)患者病情转归的价值。方法选取2019年4月—2021年1月西安市第三医院收治的118例ACI患者,根据30 d病情转归分为不良组(n=28)、良好组(n=90),比较两组基线资料、治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW水平,应用Spearman及偏相关性分析治疗前、治疗后7 d FFA、HOMAIR/PAB、RDW与mRS评分关系,采用受试者工作特征曲线(ROC)及ROC下面积(AUC)分析治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW预测病情转归的价值。结果不良组入院时NIHSS评分与良好组比较,差异有统计学意义(P<0.05);不良组治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW均高于良好组(P<0.05);治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW与mRS评分呈正相关(P<0.05);将入院时NIHSS评分控制后,治疗前、治疗后7 d FFA、HOMA-IR/PAB、RDW仍与mRS评分相关(P<0.05);治疗7 d后FFA、HOMA-IR/PAB、RDW及联合预测病情转归不良的AUC依次为0.868、0.867、0.881、0.920,均大于治疗前对应指标的AUC。结论ACI病情不良转归患者FFA、HOMA-IR/PAB、RDW升高,均与病情转归有关,联合检测有望成为预测患者病情转归的标志物,为临床提供准确、客观、量化的参考信息。
文摘Polycystic ovarian syndrome (PCOS) is an endocrine disorder that affects women of reproductive age and is characterized by hyperandrogenism, unpredictable ovulation, and a polycystic ovary shape. It is accompanied by metabolic problems, such as obesity and insulin resistance (IR). Factors contributing to PCOS include genetics, epigenetic changes, environmental factors, oxidative stress, chronic inflammation, mitochondrial dysfunction, and metabolic abnormalities. Insulin resistance is the most prevalent classical phenotype, and metformin was the first insulin-sensitizing drug to be used to study its role. Metformin, derived from galegine, inhibits mitochondrial function, activates AMPK, enhances hepatic insulin sensitivity, and lowers the risk of type 2 diabetes in PCOS patients. It also affects tumor growth, with a 30% reduction in the overall tumor onsets in T2DM patients. Metformin treatment has been linked to low rates of multiple pregnancies, increased fetal concentrations of sex hormone-binding globulin, and decreased levels of inflammatory cytokines. It can reduce the risk of endometrial cancer, type 2 diabetes mellitus, cardiovascular disease, dyslipidemia, and hypertension in women with PCOS.